MDT to Evaluate the Survival Benefit of Patients With Advanced Gastric / Colorectal Cancer

Multi-disciplinary Treatment Clinical Trial

Official title:

A Prospective, Multicenter, Prospective, Non-intervention, Controlled Trial of MDT to Evaluate the Survival Benefit of Patients With Advanced Gastric / Colorectal Cancer in Realistic Medical Practice

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03400657
• Other study ID #: CSMDT-01
• Status: Active, not recruiting
• Phase: N/A
• First received: January 2, 2018
• Last updated: January 9, 2018
• Start date: November 1, 2017
• Est. completion date: June 2020

Study information

• Verified date: January 2018
• Source: Peking University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a prospective, multicenter, non-interventional, controlled clinical study. Evaluate MDT performance and benefit analysis in patients with advanced gastric or colorectal cancer after MDT discussion under real medical practice.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 484
• Est. completion date: June 2020
• Est. primary completion date: January 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

1. Histopathological diagnosis of recurrent / metastatic gastric or colorectal cancer.

2. Participate in formal MDT discussions at the Research Center.

3. MDT decision-making at least two subjects involved in treatment.

4. Patient informed consent and signed written consent.

Exclusion Criteria:

1. Early or locally advanced gastric cancer or colorectal cancer.

2. Accept informal MDT discussions.

3. MDT decisions recommend only a single subject for treatment of patients.

4. MDT decisions recommend only palliative patients.

Related Conditions & MeSH terms

• Colorectal Neoplasms
• Multi-disciplinary Treatment

Intervention

Procedure:
• Multi-disciplinary Treatment
due to suggestion of Multi-disciplinary Treatment ,the patients would be suggested to chemotherapy or surgery.

Locations

Country	Name	City	State
China	Beijing Cancer Hospital	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Peking University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	overall survival	From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months	From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Secondary	Differences in overall survival after performing MDT at center	Differences in overall survival after performing MDT at center	1 years